Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients

Open access
ITO, Yasuhiro, YOSHIDA, Hiroshi, MARUO, Rie, MORITA, Shinji, TAKANO, Toru, HIROKAWA, Mitsuyoshi, YABUTA, Tomonori, FUKUSHIMA, Mitsuhiro, INOUE, Hiroyuki, TOMODA, Chisato, KIHARA, Minoru, URUNO, Takashi, HIGASHIYAMA, Takuya, TAKAMURA, Yuuki, MIYA, Akihiro, KOBAYASHI, Kaoru, MATSUZUKA, Fumio, MIYAUCHI, Akira·2009·Endocrine Journal

Abstract

Recent studies have demonstrated that BRAF(V600E) mutation is a common event in papillary thyroid carcinoma and a majority of these lesions have shown a direct relationship between BRAF(V600E) mutation and aggressive characteristics, including a worse patient prognosis. However, there are no studies from Japan regarding this issue in a large series with adequate postoperative follow-up periods. We investigated BRAF(V600E) mutation in 631 patients with papillary carcinoma having median follow-up periods of 83 months. The prevalence of BRAF(V600E) mutation was 38.4%, and the rate was higher in carcinoma larger than 1.0 cm but did not successively increase with tumor size. Furthermore, the prevalence did not significantly increase in cases demonstrating high-risk biological features such as clinically apparent lymph node metastasis, massive extrathyroid extension, advanced age, distant metastasis at surgery, and advanced Stage. The disease-free survival of patients with BRAF(V600E) mutation did not differ from that of those without BRAF(V600E) mutation. These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1507/endocrj.k08e-208

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 255

Metadata

Authors
ITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., KIHARA, M., URUNO, T., HIGASHIYAMA, T., TAKAMURA, Y., MIYA, A., KOBAYASHI, K., MATSUZUKA, F., & MIYAUCHI, A.
Venue
Endocrine Journal
Published
2009
Volume
56
Issue
1
Pages
89-97
ISSN
  • 0918-8959 (ISSN-L)
  • 1348-4540
OpenAlex
W1965481481
Cited by
255
References
43
FWCI
13.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients. https://app.cochat.ai/papers/10.1507/endocrj.k08e-208
The paper
ITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., KIHARA, M., URUNO, T., HIGASHIYAMA, T., TAKAMURA, Y., MIYA, A., KOBAYASHI, K., MATSUZUKA, F., & MIYAUCHI, A. (2009). BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients. Endocrine Journal. https://doi.org/10.1507/endocrj.k08e-208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.